The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.

Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

See full description in NIH Guide: PAR-08-147